PELOBIOTECH GmbH announces collaboration with HVD Life Science Vertriebs GmbH to bring revolutionary Poietis’ Next-Gen Bioprinter to Germany

Managing Directors of Pelobiotech GmbH: Peter Frost and Lothar Steeb.

Biotechnology company Pelobiotech GmbH from Planegg/Martinsried, announces a strategic partnership with HVD Life Science Vertriebs GmbH to distribute the innovative Poietis’ Next-Gen Bioprinting platform, NGB-RTM in Germany. The Bioprinter shall be a tool for advancing research in tissue engineering, regenerative medicine, and drug discovery.

The strategic partnership is anticipated to set new standards in the field of biotechnological research, providing scientists and researchers in Germany with access to state-of-the-art bioprinting technology. The Poietis’ NGB-R™ platform is expected to play a crucial role in advancing research in tissue engineering, regenerative medicine, and drug discovery, among other areas.

The Next-Gen Bioprinting platform represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI-assisted software, etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.

Dr. Peter Frost, CEO of Pelobiotech, expressed his passion for the partnership, stating, “Our alliance with HVD Life Science Vertriebs GmbH represents a significant leap forward not only for our two companies but for the entire field of biotechnological research in Germany. The Poietis’ NGB-RTM platform is at the top of bioprinting technology, enabling the creation of complex tissue structures with incredible precision. This technology has the potential to revolutionize fields from pharmaceutical testing to regenerative medicine.”

Echoing Dr. Frost's sentiments, Dr. Lothar Steeb, CEO & CSO of Pelobiotech, highlighted the impact this partnership would have on scientific discovery and innovation. “The distribution of Poietis’ NGB-RTM platform through our partnership, enables this revolutionary technology to be made available to innovative and outstanding researchers in Germany," said Dr. Steeb. "We are proud to contribute to the acceleration of research breakthroughs that can lead to major advances in healthcare and treatment modalities."